Tianjin Zhong Xin Pharmaceutical Group Corporation has reported earnings of RMB213 million ($43.5 million) for its 1QFY2021 ended March, up 25% y-o-y.
The higher earnings follow an increase in revenue for the period, which climbed 10% y-o-y from RMB1.65 billion to RMB1.83 billion on the back of higher sales in tandem with China’s recovering economy.
Gross profit for the 1QFY2021 grew 13% y-o-y to RMB753.4 million, with gross profit margin was 41.2%, up 1.2 percentage points from the previous year.
For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)